SillaJen and ABL Europe have expanded their strategic manufacturing collaboration. Under the current agreement, ABL is currently manufacturing Pexa-Vec (formerly JX-594) for SillaJen's multinational, randomized Phase 3, open-label study of Pexa-Vec in patients with advanced liver cancer. Under the expanded agreement, ABL will also provide development, manufacturing & QC release testing services for SillaJen's pipeline product, JX-970.
"Based on SillaJen's established partnership with ABL, we are pleased to further expand our agreement to include another exciting product in our pipeline," Georg Roth, Ph.D, Senior Vice President, Technical Operations at SillaJen said. "ABL has significant experience in virus manufacturing, and we are glad to be able to utilize their expertise in order to continue to expedite the development of these important oncolytic virus therapies."